Navigation Links
Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
Date:5/5/2009

, were $59.6 million, compared with $72.8 million at December 31, 2008. Management currently believes the existing cash and investment securities will provide adequate resources to fund the Company's operations into the first quarter of 2010.

Goals and Objectives

During the remainder of 2009 Poniard expects to:

  • Present progression-free survival data and safety data from two ongoing Phase 2 trials of picoplatin as first-line treatment for metastatic colorectal and castration-resistant prostate cancers (CRPC) at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO); the Company plans to hold an investor event featuring oncology experts at ASCO on Sunday, May 31;
  • Report top-line results from the pivotal Phase 3 SPEAR trial in SCLC in the second half 2009; and
  • Initiate submission of a New Drug Application with the U.S. Food and Drug Administration for picoplatin as a second-line treatment for SCLC, targeting approval and commercialization in 2010.

About Small Cell Lung Cancer

SCLC is the most aggressive form of lung cancer and tends to be widespread by the time of diagnosis. According to the American Cancer Society, in the U.S. in 2008 an estimated 32,000 new cases of SCLC were expected to be diagnosed and 52,000 SCLC patients were treated with therapy (American Cancer Society, Cancer Facts and Figures 2009). Patients with SCLC have few treatment options and a poor prognosis. Effective second-line treatment for SCLC is a major unmet medical need.

About Colorectal Cancer

CRC is the third most common cancer in both American men and women, and the third leading cause of cancer death in the U.S. In 2008, an estimated 148,810 new cases of colon and rectal cancer were expected to be diagnosed in the U.S., with an esti
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... for Advanced Drug Delivery Systems -- Focus ... STUDY OBJECTIVES ...
(Date:1/14/2014)... Corporation (Nasdaq: LMNX ) today announced that it ... on Monday, February 3, 2014. A press release announcing the ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management ... and financial results for the fourth quarter and twelve months ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a ... Leesburg, Virginia is the first in ... chamber. Dr. Susan M. Barnes , Medical ... Barnes and husband, Dr. Cole Taylor , are avid scuba ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... Amarin Corporation plc (Nasdaq: AMRN ), a clinical-stage ... positive, statistically significant top-line results from its ANCHOR trial for ... met its primary and secondary efficacy endpoints for both the ... The purpose of the ANCHOR trial was to demonstrate that ...
... and SYDNEY, April 15, 2011 HeartWare International, ... a leading innovator of less invasive, miniaturized circulatory ... advanced heart failure, today announced the presentation of ... transplantation (BTT) study, ADVANCE, showing 180-day survival, using ...
Cached Medicine Technology:Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 2Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 3Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 4Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 5Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 6Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 7Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C 8HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 2HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 3HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 4HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 5
(Date:7/9/2014)... network of signals active in almost all types of ... overdrive, and may help fuel a tumour,s uncontrolled growth, ... Cancer Research, London, identified a molecular trigger responsible for ... the cellular factory that makes the building blocks cancer ... the TOR signalling pathway, called SREBP, controls the flow ...
(Date:7/9/2014)... most common type of lung cancer, researchers have uncovered ... in forming tumors. The new knowledge may expand treatments ... changes already are available or are in clinical trials. ... from The Cancer Genome Atlas (TCGA), including researchers at ... Medical School and other institutions, studied tumors from 230 ...
(Date:7/9/2014)... New findings from Fox Chase Cancer Center paint a ... subset of breast cancers that have spread to the ... Tumors that grow into the skin, regardless of size ... classified as stage III and called "locally advanced" ... of cancer, often with poor survival. Locally advanced breast ...
(Date:7/9/2014)... used in policing injection drug users in Russia ... , A study, conducted by researchers from ... in collaboration with St. Petersburg Pavlov State University, ... on the health outcomes of a cohort of ... , Those who were arrested by police were ...
(Date:7/9/2014)... ITHACA, N.Y. Although feelings are personal and ... standard code that objectively represents emotions across different ... study by Cornell University neuroscientist Adam Anderson. , ... within the orbitofrontal cortex, an area of the ... neural code which captures an individual,s subjective feeling," ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Study cracks how the brain processes emotions 2
... ... ... Noni International (TNI) announced that Tahitian Noni® Bioactive Beverages™ contain iridoids —a bioactive ... for over 50 years and now 12 unique iridoids have been identified in the ...
... ... and after pictures and a directory for patients looking to find a plastic surgeon ... laser skin care. , ... (PRWEB) March 11, 2010 -- MyCosmeticProcedures.com is a new website focused ...
... , ... Technology Leadership with Largest Number of Highly Automated QT(sm) and QT Beat-to-Beat(sm) Studies ... Rochester, N.Y. (PRWEB) ... services and QT analysis, announced today that a top 10 pharmaceutical company has awarded ...
... LocalITCompanies.com ... be expanding nationwide. Local IT Companies connects businesses with up to three pre-screened IT service ... ... owners are entrenched in their own day to day business building operations and the thought ...
... Delphi ... Hospital in Hayward, California , ... Morrisville, NC (PRWEB) March 11, 2010 -- Delphi Healthcare Partners, Inc. ( ... provide a comprehensive OB/Gyn solution. With help from Delphi, St. Rose is in ...
... number of younger minority adults receiving medical care in settings ... the healthcare safety net). Poor, minority adults with moderate to ... to progress to kidney failure than non-Hispanic whites. These are ... Clinical Journal of the American Society of Nephrology (CJASN). ...
Cached Medicine News:Health News:12 Unique Iridoids Have Been Found in Noni Fruit 2Health News:New Website Connects Patients with Plastic Surgeons and Dermatologists 2Health News:New Website Connects Patients with Plastic Surgeons and Dermatologists 3Health News:New Website Connects Patients with Plastic Surgeons and Dermatologists 4Health News:Top 10 Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac 2Health News:LocalITCompanies.com now Helping Chicago, Dallas and Houston Businesses Find Pre-Screened IT Companies 2Health News:LocalITCompanies.com now Helping Chicago, Dallas and Houston Businesses Find Pre-Screened IT Companies 3Health News:Delphi Healthcare Partners Announces New Obstetrics/Gynecology Programs in Hayward, California 2Health News:Study: Kidney disease a big risk for younger, low-income minorities 2
Rosenbaum card fits in the pocket (3.5 by 6.5") and shows point, Jaeger and distance equivalents from 20/800 to 20/20. Uses numbers, directional Es and XO patterns. For use at 14" (35 mm). Includes f...
... contemporary reading card was designed by James ... of near point exercises including words, numbers ... 20/260, 20/200, 20/100, 20/65, 20/50, 20/40, 20/30, ... reading in English and metric, Jaeger, point ...
Standard reading test. "walked regularly..."...
Standard reading test. "Children should be..."...
Medicine Products: